Coverage
-
June 30, 2016
An Affymetrix shareholder will settle proposed class claims alleging the biotech's $1.3 billion buyout by Thermo Fisher resulted from a curtailed sales process due to a conflict of interest with its financial adviser, Morgan Stanley, according to a letter in California federal court.
1 other articles on this case.
View all »